a 12 Clinical Research Trials

Found 751 clinical trials

featured

A Phase 3, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy, Safety, And Tolerability Of Atogepant For The Prevention Of Chronic Migraine (PROGRESS)

. Treatment groups include 30mg twice daily, 60mg once daily, and placebo. This study will consist of a 4-week screening and baseline period, a 12-week double-blind treatment period

260 views
03 Aug, 2020
1 location

featured

A double-blind, randomized, parallel-group vehicle-controlled, multi-center study comparing a generic tazarotene cream, 0.05% to reference listed drug tazorac (tazarotene) cream, 0.05% and both active treatments to a vehicle control in the treatment of plaque psoriasis

A double-blind, randomized, parallel-group vehicle-controlled, multi-center study comparing a generic tazarotene cream, 0.05% to reference listed drug tazorac (tazarotene) cream, 0.05% and both active treatments to a vehicle control in the treatment of plaque psoriasis

186 views
08 Nov, 2020
1 location

featured

A Single-blind, Multi-centre, Randomised, Controlled, Non-inferiority, Clinical Study to Assess the Safety and Performance of the Neurotech Vital Compact Device Compared to the Itouch Sure Pelvic Floor Exerciser for the Treatment of Stress Urinary Incontinence in Female Patients

A Single-blind, Multi-centre, Randomised, Controlled, Non-inferiority, Clinical Study to Assess the Safety and Performance of the Neurotech Vital Compact Device Compared to the Itouch Sure Pelvic Floor Exerciser for the Treatment of Stress Urinary Incontinence in Female Patients

498 views
08 Nov, 2020
1 location

featured

Second Phase 3 Randomized, 12-Week, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of XXXXXX in Patients with Irritable Bowel Syndrome with Constipation (IBS-C)

644 views
08 Nov, 2020
1 location

featured

A Phase 2, Randomized, Double-Blind, Multicenter, Parallel-Group, Placebo-Controlled Study to Assess the Efficacy and Safety of Three Dose Levels of XP23829 in Subjects with Moderate-to-Severe Chronic Plaque-Type Psoriasis

A Phase 2, Randomized, Double-Blind, Multicenter, Parallel-Group, Placebo-Controlled Study to Assess the Efficacy and Safety of Three Dose Levels of XP23829 in Subjects with Moderate-to-Severe Chronic Plaque-Type Psoriasis